Table 2.
Association between COVID-19 severity and mean duration of hair loss onset after improvement with some variables.
| Variables | Grading of COVID-19 |
P value | MDHLOAI | P value | |||
|---|---|---|---|---|---|---|---|
| I | II | III | IV | ||||
| Sex: | |||||||
| Female | 83(20.2%) | 119(29.9%) | 156(38.0%) | 52(12.7%) | 0.03 | 252.3 | 0.001 |
| Male | 17(14.7%) | 31(26.6%) | 37(31.9%) | 31(26.7%) | 303.2a | ||
| ADLF: | |||||||
| Vitamin D deficiency | 6(13.6%) | 11(25.0%) | 21(47.7%) | 6(13.6%) | 0.250 | 15.89 ± 3.384 | 0.000 |
| Hypothyroidism | 7(18.4%) | 8(21.1%) | 16(42.1%) | 7(18.4%) | 13.79 ± 2.361 | ||
| Elevated ESR | 6(15.8%) | 6(15.8%) | 16(42.1%) | 10(26.3%) | 15.26 ± 2.777 | ||
| Diabetes | 3(8.3%) | 9(25.0%) | 16(44.4%) | 8(22.2%) | 15.81 ± 2.703 | ||
| Iron deficiency anemia | 4(16.0%) | 6(24.0%) | 10(40.0%) | 5(20.0%) | 15.52 ± 3.137b | ||
| Concurrent type of alopecia: | |||||||
| Androgenic alopecia | 23(20%) | 33(28.7%) | 39(33.9%) | 20(17.4%) | 0.038 | 15.90 ± 3.115 | 0.568 |
| Alopecia areata | 2(7.1%) | 10(35.7%) | 11 (39.3%) | 5 (17.9%) | 15.71 ± 3.196 | ||
| Cicatricial alopecia | 1(25.0%) | 2(50.0%) | 1(25.0%) | 0(0.0%) | 13.75 ± 3.304b | ||
| Smoking | 7(12.3%) | 18(31.6%) | 19(33.3%) | 13(22.8%) | 0.269 | 259.1 vs 264.0a | 0.816 |
| Addiction | 3(7.0%) | 12(27.9%) | 17(39.5%) | 11(25.6%) | 0.089 | 264.9 vs 248.2a | 0.489 |
| DHLOAI (week) (Mean ± SD) | 8.89 ± 2.039 | 7.98 ± 1.693 | 7.12 ± 1.315 | 6.81 ± 1.273 | 0.000 | ||
| MHL (week) | 9.0(3.0) | 8.0(2) | 7.0(2) | 7.0(2) | 0.000 | ||
| Median (IQR) | |||||||
MDHLOAI, Mean duration of hair loss onset after improvement; DHLOAI, Duration of hair loss onset after improvement; MHL, Median of hair loss; IQR, Inter Quartile Range; ADLF, Associated disease or Laboratory findings.
a
Mean Rank.
b
Mean ± SD.